Blog Fight CRC

Targeted therapy meets immunotherapy: a trial for metastatic KRAS G12C-mutant CRC

In this blog, we take a deep dive into the Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations (NCT06412198) clinical trial...

Fight CRC nombra consejera delegada a Anjee Davis e impulsa una audaz visión de futuro

Fight Colorectal Cancer (Fight CRC), the nation’s leading advocacy organization for colorectal cancer awareness, research, and policy, is proud to announce the promotion of Anjee Davis to Chief Executive Officer...

La Cumbre de la Innovación impulsa el cribado del cáncer colorrectal

On October 7-9, 2024, Fight Colorectal Cancer co-hosted with the inaugural Innovation Summit with Exact Sciences. This dynamic three-day event brought together public health leaders, advocates, researchers, and healthcare professionals...

Cambiar la calidad de la asistencia en el cáncer colorrectal

In response to the persistently high nationwide burden of colorectal cancer (CRC), Fight Colorectal Cancer (Fight CRC) has launched the Colorectal Cancer Care Initiative (CRCCI), a vital collaboration aimed at...

Premio a la carrera profesional para impulsar el tratamiento del síndrome de Lynch

Fight Colorectal Cancer (Fight CRC) is proud to announce that its Genetics and Family History Advisory Council is leading an initiative, alongside nearly 150 patient advocacy organizations, medical societies, and...

Actualizaciones de ESMO

Patients with microsatellite instability (MSI)/mismatch repair deficient (dMMR) colon cancer who undergo surgery may benefit from receiving neoadjuvant immunotherapy. Standard-of-care chemotherapy offers limited benefit to patients with MSI-H/dMMR colon cancer,...